The patients were treated with an iodine-131 radiolabeled tumor necrosis therapy antibody (131I-TNT). Results showed that approximately 90% of patients treated with 131I-TNT had stable disease or better, with 3.7% achieving complete responses, 30.8% achieving partial responses involving at least 50% shrinkage of their tumors and 55.1% achieving stable disease.
According to the study, radioimmunotherapy with iodine-131 chimeric TNT was well tolerated and can be used intravenously or intratumorally to treat refractory tumors of the lung.
While the overall response rate in patients treated intravenously and intratumorally were approximately 36% and 33%, respectively, the severity of side effects related to the drug was lower in patients treated intratumorally.
“This compelling tumor response data in advanced lung cancer and the clinical data we have generated in brain cancer demonstrate TNT’s ability to clinically benefit people suffering from cancer,” stated Joe Shan, director of clinical development at Peregrine Pharmaceuticals. “We are looking forward to initiating clinical enrollment in our brain cancer trial in collaboration with the New Approaches to Brain Tumor Therapy consortium.”